Plant Name: Rauvolfia verticillata
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 6.150E-12 | 1.339E-07 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 2.023E-10 | 2.203E-06 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 5.662E-10 | 4.110E-06 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 2.264E-09 | 7.041E-06 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 2.264E-09 | 7.041E-06 | ADRA2A, ADRA2B, ADRA2C |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.264E-09 | 7.041E-06 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0010700; negative regulation of norepinephrine secretion | 3.162E-08 | 5.297E-05 | ADRA2A, ADRA2B, ADRA2C |
| MF | GO:0005488; binding | GO:0051379; epinephrine binding | 3.162E-08 | 5.297E-05 | ADRA2A, ADRA2B, ADRA2C |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 5.982E-08 | 8.684E-05 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.240E-07 | 1.588E-04 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.559E-07 | 2.787E-04 | CA13, CA7, CA9 |
| BP | GO:0009987; cellular process | GO:0071880; adenylate cyclase-activating adrenergic receptor signaling pathway | 6.395E-07 | 5.802E-04 | ADRA2A, ADRA2B, ADRA2C |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 9.919E-07 | 8.307E-04 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 1.792E-06 | 1.301E-03 | CYP1A2, CYP2C9, CYP2D6, CYP3A4, NPC1 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 2.186E-06 | 1.442E-03 | CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 2.581E-06 | 1.606E-03 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 3.332E-06 | 1.860E-03 | ADRA2A, ADRA2B, ADRA2C |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 3.332E-06 | 1.860E-03 | CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.971E-06 | 2.109E-03 | CA13, CA7, CA9 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 4.095E-06 | 2.123E-03 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 7.333E-06 | 3.327E-03 | CA13, CA7, CA9 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 9.921E-06 | 4.236E-03 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| BP | Unclassified; | GO:0019229; regulation of vasoconstriction | 1.878E-05 | 7.181E-03 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0009987; cellular process | GO:0019896; axonal transport of mitochondrion | 2.615E-05 | 9.335E-03 | HIF1A, MAPT |
| BP | GO:0032501; multicellular organismal process | GO:0070472; regulation of uterine smooth muscle contraction | 2.615E-05 | 9.335E-03 | ADRA2B, ADRA2C |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 2.984E-07 | 9.874E-06 | CYP2C9; CYP2D6; CYP1A2; CYP3A4 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 3.750E-07 | 9.874E-06 | CYP2C9; CYP2D6; CYP1A2; CYP3A4 |
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 3.443E-07 | 9.874E-06 | CA7; CA9; CA13 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.839E-06 | 3.631E-05 | CYP2C9; CYP1A2; CYP3A4 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 2.157E-05 | 3.407E-04 | CYP2C9; CYP1A2; CYP3A4 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 4.334E-05 | 5.706E-04 | CYP2C9; CYP1A2; CYP3A4 |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 3.568E-04 | 4.026E-03 | ADRA2C; ADRA2B; ADRA2A |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 1.548E-03 | 1.358E-02 | ADRA2C; ADRA2B; ADRA2A |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.093E-03 | 1.079E-02 | CYP1A2; CYP3A4 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 3.396E-03 | 2.683E-02 | HIF1A; NFKB1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 4.001E-03 | 2.793E-02 | CYP2C9; CYP2D6 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 6.176E-03 | 3.485E-02 | LMNA; NFKB1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 5.839E-03 | 3.485E-02 | RAB9A; NFKB1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 4.243E-03 | 2.793E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ADRA2C; MAPT |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9; HIF1A |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ADRA2C; ADRA2A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; HIF1A |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADRA2B |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; NPSR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | ADRA2C |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADRA2C |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6 |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | ADRA2C |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | CA9; NFKB1; HIF1A |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2C; ADRA2B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C |